NMN (Nicotinamide Mononucleotide) — Stack & Timing
Educational timing and stacking information based on how NMN (Nicotinamide Mononucleotide) has been studied. Not a prescription. Not medical advice.
This is educational information only. Consult a healthcare provider before starting any supplement.
Stack & Timing Guidance
Educational summary based on how NMN (Nicotinamide Mononucleotide) has been studied and commonly used.
Commonly studied timing
Morning dosing is consistently favored by multiple experts (Huberman, Patrick, Brecka) due to NAD+'s role in energy metabolism and its potentially stimulating effects, which may interfere with sleep if taken later in the day. No RCT evidence definitively establishes optimal timing, so this reflects expert consensus rather than controlled trial data.
Dose ranges used in studies
Human RCTs have studied doses ranging from 250 mg to 1200 mg per day, with many trials clustering around 250–500 mg; higher doses up to 1000–1200 mg have also been evaluated for safety and efficacy without clear evidence of a superior dose.
↑ These are ranges from research studies, not personal dosing recommendations. Discuss with a clinician.
Commonly paired with
Resveratrol is thought to activate SIRT1, a sirtuin enzyme that requires NAD+ as a cofactor, potentially amplifying NMN's effects on NAD+-dependent pathways
NMN metabolism may increase methylation demand; TMG is used as a methyl donor to potentially offset methylation depletion associated with elevated NAD+ synthesis
Vitamin D3 is commonly co-supplemented as part of a longevity-focused stack, with both compounds implicated in metabolic health and aging pathways
Omega-3s are frequently included in longevity and cardiovascular health stacks alongside NMN, given complementary effects on inflammation and metabolic function
Safety & interactions
Available RCT evidence suggests NMN is generally well-tolerated in healthy adults at doses up to 1200 mg/day over study durations, with no serious adverse events reported in safety-focused trials. Long-term safety data beyond 12 months in humans remains limited, and most studies are of moderate quality.
- •Potential interaction with chemotherapy or cancer treatments due to NAD+'s role in DNA repair and cell survival pathways — theoretical concern, not established in human trials
- •May theoretically interact with medications affecting methylation pathways (e.g., methotrexate) given NMN's impact on NAD+ metabolism and methyl group utilization
Individuals with active cancer or a history of hormone-sensitive cancers should exercise caution and consult a physician, as NAD+ elevation may theoretically support tumor cell survival. Pregnant or breastfeeding individuals should avoid use due to insufficient safety data. Those on complex medication regimens should seek medical advice before use.